Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging
Status:
Completed
Trial end date:
2018-11-06
Target enrollment:
Participant gender:
Summary
1. It is a multicenter, open-label, sing arm study to evaluate the effects of treatment of
Rosuvastatin 10-20mg in volume and morphology of atherosclerotic plague by reducing
LDL-C level to or less than 70mg/dl.
2. Ischemic stroke patients will be enrolled within 1 month after stroke onset.
3. Patients will be visited at 0m, 1m, 3m, 6m, 9m, 12m, 18m and 24m.
Phase:
Phase 4
Details
Lead Sponsor:
Beijing Tiantan Hospital Ministry of Science and Technology of the People´s Republic of China